Cytocare Inc. (NASDAQ:CYTI) said that it has acquired exclusive worldwide rights to diagnostic, prognostic and therapeutic uses of certain hybridoma cell lines and murine monoclonal antibodies specific for prostate cancer. The patented molecules were licensed from the Sloan-Kettering Institute for Cancer Research. Irvine, Calif.-based Cytocare is developing a family of molecules to diagnose and treat benign prostatic hypertrophy and prostate cancer. The company's shares closed unchanged at $1
TSI Corp. said it has filed a 2.3 million-share offering of common stock in which the company will sell 2 million shares and the remainder will be offered by selling shareholders. The Worcester, Mass., company (NASDAQ:TSIN) is developing disease models, toxicology tests and animals for use as bioreactors for pharmacological substances. It also provides a variety of preclinical and clinical testing services. TSI said the selling shareholders will not include executive officers or directors. The
Vestar Inc., which develops drugs to treat patients with cancer and serious infections, on Tuesday filed for a public offering of 2.5 million shares of common stock. Vestar shares (NASDAQ:VSTR) closed down 75 cents at $16.75 on Tuesday. Vestar's AmBisome liposomal formulation of the anti-fungal amphotericin B is sold in the United Kingdom, Ireland and Mexico. Fujisawa USA Inc. is developing AmBisome in the United States. Earlier this month, the San Dimas, Calif., company reported promising
Advanced Tissue Sciences Inc. said Tuesday it has filed for a 2 million-share offering of common stock. The La Jolla, Calif., company (NASDAQ:ATISA), which recently changed its name from Marrow-Tech Inc., said the proceeds would be used to accelerate development of its skin-related products. The company is developing products for therapeutic and laboratory applications that involve growth of human tissue outside of the body. In November, the Food and Drug Administration approved expansion of
Alteon Inc.'s aminoguanidine compound has been shown to inhibit the development of diabetic retinopathy in rats. Diabetes is the leading cause of adult blindness in the United States. Pathologic retinal changes are found in virtually 100 percent of patients having type I (juvenile onset) diabetes for 15 years or longer and 70 percent of patients having type II (adult onset) diabetes for 15 years or longer. The Northvale, N.J., company (NASDAQ:ALTN) is conducting Phase I trials of the compound
Roberts Pharmaceutical Corp., which acquires and develops late-stage pharmaceutical products, said Monday that it has signed a letter of intent under which Yamanouchi Pharmaceutical Co. Ltd. will buy 4 million newly issued shares of Roberts stock for $95 million. The Eatontown, N.J., company (NASDAQ:RPCX) said it will use the money to accelerate its product development programs and fund possible acquisitions. Roberts' pipeline currently includes treatments for cancer, respiratory disease
Alpha 1 Biomedicals Inc. on Monday said it has completed its acquisition of all U.S. rights to Thymosin alpha 1 from Hoffmann-La Roche Inc. Alpha 1 (NASDAQ:ALBM) purchased exclusive rights to the drug from Roche in September 1990 for treatment of chronic hepatitis B, lung cancer and as an adjuvant for vaccines. It further acquired exclusive rights to Roche's Thymosin alpha 1 patents in 21 countries last March. Roche of Nutley, N.J., was assigned the U.S. composition of matter patent on the
Stock of Synergen Inc. rose $2.88 to $59.13 on Monday after Alex. Brown & Sons Inc. analyst David Webber repeated his "strong buy" recommendation and raised his earnings estimates for the Boulder, Colo., company. Webber predicted that Synergen shares (NASDAQ:SYGN) would rise 50 percent to 100 percent next year. He based his forecast on strong data from Phase II trials of Antril interleukin-1 receptor antagonist reported last month. The results imply that "Synergen has a good shot at getting
Cytogen Corp. on Monday said it has started Phase I trials of its OncoTc NSL380 for imaging non-small cell lung cancer primary tumors and diseased lymph nodes. The product is a monoclonal antibody fragment attached to the technetium-99m radioisotope. Cytogen (NASDAQ:CYTO) received approval for the trials in October, but delayed until it could produce enough whole monoclonal antibodies to begin trials for an imaging agent for colorectal cancer, said Robert Maguire, director of clinical
Sepracor Inc. has signed an agreement with Japan's Tanabe Seiyaku Co. Ltd. to produce commercial quantities of diltiazem, an anti-hypertensive and angina drug, using Sepracor's chiral biocatalysis and membrane reactor technology. Sepracor (NASDAQ:SEPR) uses biological methods to produce pure isomer forms of drugs. "Sepracor is providing a much more efficient, low-cost process for synthesizing the pure isomer," said Dr. Robert Bratzler, general manager of Sepracor's chiral chemicals division
Marion Merrell Dow Inc. and Alza Corp. said Friday that a U.S. District Court in Newark, N.J., has denied a request by Ciba- Geigy Corp. for a preliminary injunction to prevent sales of Alza's Nicoderm transdermal nicotine patch. The ruling leaves both MMD, Alza's marketing partner, and Ciba-Geigy free to market their respective patches. The patches are the only ones with Food and Drug Administration marketing approval. Among the five suits between companies jockeying for market position, Ciba
Chiron Corp. and Cytogen Corp. announced Friday that they will have products reviewed by a Food and Drug Administration panel in January. Chiron's Proleukin interleukin-2 to treat metastatic renal cell carcinoma, acquired as part of the purchase of Cetus Corp., will be reviewed on Jan. 17 by the Biological Response Modifiers advisory committee. Emeryville, Calif.-based Chiron shares (NASDAQ:CHIR) rose $1 to $62.75. This is the drug's second time before the committee. In July 1990, the panel
Corvas International Inc. has filed for an initial public offering of 2.5 million shares of common stock with a proposed price range of $10 to $12 per share. Corvas of San Diego is developing drugs to treat thrombosis and associated vascular diseases. The company has one drug, Corsevin M, in Phase I trials. The monoclonal antibody-based anti-thrombotic binds to Factor VII, a factor involved in the early stages of coagulation. Centocor Inc. of Malvern, Pa., in November acquired a worldwide
ImmuLogic Pharmaceutical Co. on Friday said it has filed for a public offering of 2 million shares of common stock. ImmuLogic shares (NASDAQ:IMUL) closed down 75 cents on Friday at $18.50. The company sold 2 million shares of common stock at $10 a share in a May initial public offering. The company had hoped to sell 3 million shares priced between $14 and $16. In November, the company signed a deal that could be worth more than $60 million with Marion Merrell Dow Inc. to jointly develop
VimRx Pharmaceuticals Inc. said Friday that it has filed for a public offering of 1,000 units priced at $5,000 per unit. Each unit will consist of common stock and an identical number of class A warrants to purchase common stock. The number of shares will be determined immediately prior to the offering. D.H. Blair & Co. Inc. is the underwriter. The stock (NASDAQ:VMRX) closed unchanged Friday at $1.38. VimRx of Stamford, Conn., is developing drugs based on hypericin, a natural compound derived
Oncogene Science Inc. said Friday that it netted $17.1 million in a secondary offering of 3.68 million shares at $5.50 per share. The shares sold include 200,000 shares sold by a stockholder and underwriter Wertheim Schroder and Co.'s 480,000-share overallotment. After the offering, the Uniondale, N.Y., developer of cancer diagnostics and therapeutics has 14.9 million shares outstanding. The stock (NASDAQ:ONCS) rose 38 cents to $6.63 on Friday. (c) 1997 American Health Consultants. All rights
Biogen Inc. shares fell $3.50 to $38.75 on Friday after Goldman Sachs analyst Jeffrey Swarz reduced his rating to a "hold" and removed the stock from Goldman's focus and recommended for purchase lists. Swarz wrote that his primary reason for the change was the price level of the Cambridge, Mass., company's stock (NASDAQ:BGEN), which has appreciated fourfold since February 1990 and 44.8 percent this year. Swarz also lowered his 1992 earnings estimate to 60 cents from $1 because the company
Idexx Laboratories Inc. said it has renegotiated the terms of its proposed acquisition of the assets of VetTest S.A., which manufactures biochemical monitoring tests for the animal health care market. Under the new terms, the purchase price would be $5 million in cash and about 200,000 shares of newly issued Idexx common stock (NASDAQ:IDXX). VetTest, a privately held Swiss company, would be entitled to 80,000 additional shares contingent on performance measures. If the acquisition is completed
Donald E. Mosier has resigned as chief scientific officer and a director of Lidak Pharmaceuticals Inc., citing disagreements with the company over restructuring plans and scientific issues. In his letter of resignation, dated Dec. 13, Mosier said, "I do not have confidence that the Board and the management of Lidak as presently constituted will be able to lead the company out of its current problems." Mosier also wrote that he disagreed with some of the company's scientific claims or felt that
DynaGen Inc. said it has signed an agreement with The Royal Tropical Institute of Amsterdam, the Netherlands, for rights to antibodies to be used in the development of tests to diagnose tuberculosis and other mycobacterial diseases. The Cambridge, Mass., company said the license will expand its portfolio of diagnostic tests for mycobacterial diseases. DynaGen noted that TB has been resurging in the United States as a consequence of AIDS. DynaGen shares (NASDAQ:DYGN) closed up 50 cents at $6.88
Cytocare Inc. (NASDAQ:CYTI) said that it has acquired exclusive worldwide rights to diagnostic, prognostic and therapeutic uses of certain hybridoma cell lines and murine monoclonal antibodies specific for prostate cancer. The patented molecules were licensed from the Sloan-Kettering Institute for Cancer Research. Irvine, Calif.-based Cytocare is developing a family of molecules to diagnose and treat benign prostatic hypertrophy and prostate cancer. The company's shares closed unchanged at $1